Jasochlor 80 mg/5 ml (Syrup)
60 ml bottle: ৳ 14.91
Medicine Details
| Category | Details |
|---|---|
| Generic | Chloroquine phosphate |
| Company | Jayson pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of malaria
- Prophylaxis and suppression of malaria
- Treatment of amoebic hepatitis and abscess
- Treatment of discoid lupus erythematosus
- Treatment of systemic lupus erythematosus
- Treatment of rheumatoid arthritis
Composition
- Tablet: Chloroquine Phosphate BP 250 mg equiv. to approx. 150 mg of Chloroquine base
- Syrup: Chloroquine Phosphate BP 80 mg equiv. to approx. 50 mg of Chloroquine base
Pharmacology
4-aminoquinoline antimalarial and amoebicidal agent
Dosage & Administration
- For the treatment of acute attack of malaria:
- Adults and children: 25 mg of chloroquine base per kg body-weight given over 3 days
- For clinical prophylaxis:
- Adult: An oral dose equivalent to 300 mg chloroquine base is given every 7 days for about one week before, during, and for at least 4 weeks after exposure
- Children: A weekly oral dose of 5 mg per kg body-weight
- For hepatic amoebiasis: 600 mg base daily for two days, followed by 300 mg base daily for at least 2-3 weeks
- For discoid and systemic lupus erythematosus: Suggested oral dose is 150 mg of base daily, reducing gradually once symptoms have been controlled
- For rheumatoid arthritis: Adult: 150 mg of base daily, some clinicians suggest that treatment should be given for only 10 months in each year
Interaction
- Neostigmine
- Pyridostigmine
- Antacids
- Kaolin
- Cimetidine
- Ranitidine
- Quinine
- Mefloquine
- Amodiaquine
- Artemisinin
- Metronidazole
- Ampicillin
Contraindications
- Known or suspected chloroquine resistance in P. falciparum
- Hypersensitivity
- Retinal damage
- Concurrent therapy with hepatotoxic drugs
Side Effects
- Gastro-intestinal: Nausea, vomiting and diarrhoea
- Psychological: Psychotic episodes, anxiety and personality changes
- Visual disturbances: Blurred vision, difficulties in focusing, keratopathy, retinopathy
- Haematological: Aplastic anaemia, agranulocytosis, thrombocytopenia, neutropenia
- Others: Loss of hair, bleaching of hair pigment, bluish black pigmentation of the mucous membranes and skin, photosensitivity, tinnitus, reduced hearing, nerve deafness, uromyopathy and myopathy
Pregnancy & Lactation
The use of chloroquine during pregnancy should be avoided except in the suppression or treatment of malaria when in the judgement of the physician the benefit outweighs the possible hazard. Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother
Precautions & Warnings
- The eyes should be examined before starting long-term treatment and should be monitored subsequently
- Visual disturbances may render patients unfit to take charge of vehicles or machinery
- Care is necessary in administering to patients with impaired liver or renal function or to those with prophyria, psoriasis, or a history of epilepsy
- Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency should be observed for haemolytic anaemia during chloroquine treatment
Therapeutic Class
Anti-malarial drugs
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children